A Requisite Role for Induced Regulatory T Cells in Tolerance Based on Expanding Antigen Receptor Diversity  by Haribhai, Dipica et al.
Immunity
ArticleA Requisite Role for Induced
Regulatory T Cells in Tolerance
Based on Expanding Antigen Receptor Diversity
Dipica Haribhai,1 Jason B. Williams,1 Shuang Jia,2 Derek Nickerson,5 Erica G. Schmitt,1 Brandon Edwards,1
Jennifer Ziegelbauer,1 Maryam Yassai,6 Shun-Hwa Li,3 Lance M. Relland,1 Petra M. Wise,5 Andrew Chen,5
Yu-Qian Zheng,5 Pippa M. Simpson,3 Jack Gorski,6 Nita H. Salzman,4 Martin J. Hessner,2 Talal A. Chatila,5,*
and Calvin B. Williams1,*
1Section of Rheumatology
2Max McGee National Research Center for Juvenile Diabetes
3Section of Quantitative Health Sciences
4Section of Gastroenterology
Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226, USA
5Division of Immunology, Allergy and Rheumatology, Department of Pediatrics, The David Geffen School of Medicine at the University of
California at Los Angeles, Los Angeles, CA 90095, USA
6Blood Research Institute, Blood Center of Wisconsin, Milwaukee, WI 53226, USA
*Correspondence: tchatila@mednet.ucla.edu (T.A.C.), cwilliam@mcw.edu (C.B.W.)
DOI 10.1016/j.immuni.2011.03.029SUMMARY
Although both natural and induced regulatory T
(nTreg and iTreg) cells can enforce tolerance, the
mechanisms underlying their synergistic actions
have not been established. We examined the func-
tions of nTreg and iTreg cells by adoptive transfer
immunotherapy of newborn Foxp3-deficient mice.
As monotherapy, only nTreg cells prevented disease
lethality, but did not suppress chronic inflammation
and autoimmunity. Provision of Foxp3-sufficient
conventional T cells with nTreg cells reconstituted
the iTreg pool and established tolerance. In turn,
acutedepletionof iTregcells in rescuedmice resulted
in weight loss and inflammation. Whereas the tran-
scriptional signatures of nTreg and in vivo-derived
iTreg cells were closely matched, there was minimal
overlap in their T cell receptor (TCR) repertoires.
Thus, iTreg cells are an essential nonredundant
regulatory subset that supplements nTreg cells, in
part by expanding TCR diversity within regulatory
responses.
INTRODUCTION
‘‘Natural’’ regulatory T (nTreg) cells that express the forkhead or
winged helix transcription factor Foxp3 arise in the thymus,
where they require high affinity T cell receptor (TCR) ligation by
an agonist peptide-MHC complex for Foxp3 induction (Jordan
et al., 2001; Relland et al., 2009). ‘‘Induced’’ Foxp3+ regulatory
T (iTreg) cells can be generated from naive, mature CD4+
‘‘conventional’’ T (Tconv) cells during T cell activation by both
TGF-b dependent and independent mechanisms (Chen et al.,
2003; Schallenberg et al., 2010). The PD-L1-PD-1 ligand-receptor pathway and environmental factors, such as some
aryl hydrocarbon receptor agonists and the vitamin A metabolite
all-trans retinoic acid, enhance iTreg cell conversion, suggesting
that control of iTreg cell production is biologically important
(Coombes et al., 2007; Francisco et al., 2009; Quintana et al.,
2008). Collectively, Treg cells are required for the maintenance
of immunological tolerance, as illustrated by the fatal autoim-
mune lymphoproliferative disease that develops in neonatal
mice and humans deficient in Foxp3 (Brunkow et al., 2001; Cha-
tila et al., 2000).
Both iTreg and nTreg cells have suppressive function,
measured by their capacity to inhibit T cell proliferation and
suppress experimental autoimmune disease by adoptive trans-
fer immunotherapy (Fantini et al., 2006; Huter et al., 2008b; Mot-
tet et al., 2003). However, the relative contribution of each cell
type to the peripheral Treg cell compartment and to the mainte-
nance of tolerance is largely unknown and may depend upon the
particular model used to examine this question (Curotto de
Lafaille and Lafaille, 2009; Haribhai et al., 2009).
The production of iTreg cells in vivo has been examined in
several experimental systems. After adoptive transfer, poly-
clonal and TCR transgenic monoclonal populations of CD4+
T cells can be induced to express Foxp3, either during homeo-
static expansion or by chronic intravenous antigen exposure
(Apostolou and von Boehmer, 2004; Curotto de Lafaille et al.,
2004). Oral administration of antigen also generates iTreg cells,
and these contribute to antigen-specific tolerance in the gut
(Mucida et al., 2005). When naive CD4+ Foxp3 Tconv cells
are transferred into Rag1–/– mice, the mice develop colitis, and
10% of the CD4+ mesenteric lymph node cells induce Foxp3
expression. These in vivo derived iTreg cells contribute to
successful adoptive transfer immunotherapy with nTreg cells
and to tolerance in the intestinal tract (Haribhai et al., 2009). In
contrast to these studies, peripheral conversion is not observed
after an acute viral infection, and only 2%–3% of proliferating
TCR transgenic Tconv cells upregulate Foxp3 after immunization
(Fontenot et al., 2005; Haribhai et al., 2007). TCR repertoireImmunity 35, 109–122, July 22, 2011 ª2011 Elsevier Inc. 109
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Tconv and Treg TCR repertoires, depending upon the approach
used for the study (Hsieh et al., 2004; Lathrop et al., 2008;
Pacholczyk et al., 2006;Wong et al., 2007). Thus, some contribu-
tion of iTreg cells to the peripheral Treg cell pool seemsplausible,
even in healthy animals.
Gene expression studies have compared the transcriptional
signature of nTreg cells with that of iTreg cells produced
in vivo and in vitro using a variety of conditions (Feuerer et al.,
2010; Haribhai et al., 2009; Hill et al., 2007). These studies
confirm that while iTreg cells share a fraction of the canonical
nTreg cell transcriptosome, they also contain a large number
of differentially enriched transcripts. This divergence is not
attributable to T cell activation, but correlates with the method
used to generate the iTreg cells. Maintenance of the iTreg tran-
scriptional signature and the generation of suppressive function
depend upon Foxp3 expression, analogous to the role of Foxp3
in nTreg cells (Haribhai et al., 2009; Hill et al., 2007). Methylation
studies of conserved CpG motifs in the Foxp3 promoter also
identify epigenetic differences between nTreg and iTreg cells,
with the former showing more extensive demethylation and
stable Foxp3 expression (Floess et al., 2007; Polansky et al.,
2008). These data are consistent with the loss of Foxp3 expres-
sion in adoptive transfer studies using iTreg cells generated
in vitro (Selvaraj and Geiger, 2007). Collectively, these genomic
studies imply that peripheral Treg cells may be a complex
mixture of subphenotypes able to interconvert (Feuerer et al.,
2010). The transcriptional programs of stable iTreg cells derived
in vivo and stable nTreg cells isolated under the same conditions
from the same hosts have not been compared and may provide
additional insights into the mechanisms of iTreg cell function.
Although iTreg cells can clearly develop in vivo, the iTreg cell
contribution to immunologic tolerance remains to be estab-
lished. This question was first evaluated with neonatal adoptive
transfer immunotherapy for treating C57BL/6 scurfy mice, which
express amutated and nonfunctional Foxp3 protein and develop
a fatal autoimmune syndrome. Mice treated with either nTreg or
iTreg cells alone showed a reduction in the pathological manifes-
tations of the disease at the conclusion of the studies, 21 days
after Treg cell transfers (Fontenot et al., 2003; Huter et al.,
2008a). Tolerance at steady state in mature mice and the effect
of combined therapy with both iTreg and nTreg cells were not
considered in these studies.
In this report, we examined the respective roles of nTreg and
iTreg cells by adoptive transfer immunotherapy of newborn
Foxp3-deficient mice. Results demonstrated that in vivo-derived
iTreg cells, which comprised 15% of the peripheral Foxp3+
Treg cell pool, acted in concert with nTreg cells to enforce toler-
ance by mechanisms that involved expansion of the TCR reper-
toire of regulatory responses.
RESULTS
Rescue of Foxp3-Deficient Mice
The capacity of adoptively transferred Treg cell populations to
rescue Foxp3-deficient mice is a comprehensive test of Treg
cell function. We utilized BALB/c Foxp3K276X mice, which lack
Foxp3 protein expression (Lin et al., 2005). More than 90% of
BALB/c Foxp3K276X mice rapidly succumb to the autoimmune110 Immunity 35, 109–122, July 22, 2011 ª2011 Elsevier Inc.lymphoproliferative disease associated with Foxp3-deficiency
within 21 days of birth, and no mice live beyond 32 days.
Mice with the same mutation bred on to the C57BL/6 back-
ground live markedly longer, making it more difficult to evaluate
the long-term effects of adoptive transfer immunotherapy in
C57BL/6 mice (Figure 1A, BALB/c n = 68, C57BL/6 n = 19).
Most subsequent experiments used BALB/c Thy1.2+ Foxp3K276X
mice to provide a stringent therapeutic test with a clear endpoint
in untreated mice.
To determine the number of Treg cells and the time course
needed for successful therapy, we injected603 106 unfractio-
nated syngenic splenocytes into the peritoneal cavity of newborn
Foxp3K276X mice. These inocula contained 0.9 3 106 nTreg
cells and 5.8 3 106 Tconv cells. Most mice survived to 50 days
(Figure 1B, 91%, 177/194 mice), although survival decreased
slightly at 100 days (86%, 166/194 mice). Surviving mice ex-
hibited normal weight gain and were fertile (data not shown).
Reduction of the inocula to 5 3 106 purified Thy1.1+ CD4+
T cells, containing 0.73 106 nTreg cells, also resulted in effec-
tive rescue. Most mice survived to 50 days (89%, 40/45 mice),
and survival decreased slightly by 100 days (82%, 37/45 mice).
There was no statistical difference in survival between the two
treatments at 50 days and at 100 days. Treated mice had normal
percentages of naive T cells and lacked the elevated serum
concentrations of proinflammatory cytokines seen in Foxp3K276X
mice (Figures 1C and 1D). Thus neonatal adoptive transfer
immunotherapy with CD4+ T cells was sufficient to rescue
Foxp3-deficient mice.
Monotherapy with nTreg or iTreg Cells
Using these CD4+ T cell numbers as an estimate, we examined
the capacity of different Thy1.1+ T cell populations to reconsti-
tute Thy1.2+ Foxp3-deficient recipient mice. All transferred
populations were purified by cell sorting from Foxp3EGFP mice,
which contain a bicistronic Foxp3 locus that coexpresses
Foxp3 and the enhanced green fluorescent protein (EGFP) under
control of the endogenous Foxp3 promoter and enhancer
elements (Haribhai et al., 2007). All mice were followed for at
least 50 days to allow the development of partially treated
phenotypes.
Neonatal transfer of 0.125 3 106 Thy1.1+ nTreg cells (CD4+
EGFP+) isolated from Foxp3EGFP mice failed to prolong survival
(n = 16, survival data not shown). Mice lived longer but died after
30–45 days (n = 9) when 0.25 3 106 Thy1.1+ nTreg cells were
used for the rescue. Increasing the dose to 0.5 3 106 cells
resulted in the survival of all mice to 50 days (n = 26). Mice that
received 0.5 3 106 nTreg cells gained weight, but at a reduced
rate compared to controls (Figure 2A). Flow cytometry analysis
of reconstituted mice showed 7%–10% of CD4+ cells in the
lymph nodes were EGFP+ nTreg cells, irrespective of the treat-
ment group (Figures 2B and 2C). The average number of lympho-
cytes recovered from peripheral lymphoid tissues (spleens,
brachial, axillary, and superficial inguinal and mesenteric lymph
nodes) of mice treated with 0.5 3 106 nTreg cells was signifi-
cantly higher than that of untreated healthy animals (233 ±
163 106 cells versus 75 ± 2.53 106 cells, p = 0.0003). Similarly,
the total number of CD4+ T cells (71 ± 53 106 versus 15 ± 1.63
106 cells, p = 0.0003) and nTreg cells (6 ± 0.63 106 versus 1.7 ±
0.23 106 cells, p = 0.0003) in this collection of lymph nodes and
Figure 1. Adoptive Transfer Immunotherapy of Newborn Foxp3-Deficient Mice
(A) Kaplan-Meier survival curves of Foxp3K276X mice bred onto the BALB/c (n = 68) and C57BL/6 (n = 19) backgrounds.
(B) Kaplan-Meier survival curves of BALB/c Foxp3K276X mice rescued by neonatal intraperitoneal adoptive transfer with 60 3 106 unfractionated splenocytes
(n = 194) or purified 5 3 106 CD4+ T cells (n = 45).
(C) Representative flow cytometry analysis of lymphocytes from the indicated mice stained for naive (CD62Lhi CD44lo) and effector or memory (CD62Llo CD44hi)
CD4+ T cells. For these and all subsequent representative FACS plots, numbers indicate the mean percent of cells in the quadrant. Groups included untreated
Foxp3K276X mice, n = 4; Foxp3K276X mice rescued (R) with unfractionated splenocytes, n = 4; 6- to 8-week-old Foxp3EGFP control mice, n = 16. The CD4+ Thy1.2+
gate identified host T cells in the rescued mice.
(D) The serum concentration of proinflammatory cytokines from the indicated mice (n = 10 for all groups). *p < 0.05, **p < 0.005, ***p < 0.0005, ns, not significant.
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group relative to age-matched controls (Figures 2D and 2E).
Treated mice also had a reduced frequency of naive
(CD62LhiCD44lo) host T cells (Figures 2F and 2G). These data es-
tablished 0.5 3 106 nTreg cells as sufficient for survival to
50 days, although transfer recipients had splenomegaly, lym-
phoproliferation, and host T cell activation. Serum amounts of
TNF-a, IFN-g, and IL-17A were also increased, suggesting
incomplete tolerance (Figure 2H). Doubling the dose to 1.0 3
106 nTreg cells did not significantly increase weight gain,
decrease most disease manifestations, or change the number
of nTreg cells recovered (Figures 2A–2H). It therefore seemed
unlikely that an additional increase in the nTreg cell dose above
1 3 106 cells would appreciably improve the therapeutic
outcome. Furthermore, the 1.0 3 106 nTreg cell dose exceeded
the average number of nTreg cells found in 60 3 106 unfractio-
nated splenocytes, so we used 1.03 106 nTreg cells in all subse-
quent experiments. Replacing the nTreg cells with 1.0 3 106
in vitro-generated iTreg cells had no significant effect on sur-
vival, and all mice died within 30 days (n = 6, data not shown).
In summary, nTreg cells survived and expanded in BALB/c
Foxp3K276X mice but were not sufficient to maintain tolerance.In vitro-generated iTreg cells did not substitute for nTreg cells,
at least when numerically equivalent cell doses were compared.
Therapy with iTreg and nTreg Cell Combinations
In Foxp3K276X mice treated with nTreg cells alone, all host CD4+
Tconv cells carried a nonfunctional Foxp3 allele and could not
become iTreg cells. In the experiments with either unfractionated
splenocytes or purified CD4+ T cells (Figure 1), CD4+ Tconv cells
might have given rise to iTreg cells that acted synergistically with
nTreg cells to promote tolerance, aswe have previously shown in
an experimental model of colitis (Haribhai et al., 2009). To further
evaluate the contribution of iTreg cells to tolerance, we
combined nTreg cells with Tconv cells in the rescue experi-
ments. Adoptive transfer of 13 106 Thy1.2+ nTreg cells together
with 43 106 Thy1.1+ Tconv cells resulted in the survival of 28/29
transfer recipients and in improved weight gain (Figure 3A). At
50 days, Thy1.1+ in vivo derived iTreg cells comprised 1% of
CD4+ T cells, 15% of the total EGFP+ Treg cell pool, and approx-
imately one-third of the surviving Thy1.1+ cells (Figures 3B and
3C). The frequency of nTreg cells was similar between the treat-
ment groups (Figure 3C), and the total number of Treg (iTreg +
nTreg) cells recovered from the spleens and peripheral lymphImmunity 35, 109–122, July 22, 2011 ª2011 Elsevier Inc. 111
Figure 2. The Effect of nTreg Cell Monotherapy on Therapeutic Outcome
(A) Linear regression analysis of weight change over time following intraperitoneal adoptive transfer of the indicated number of nTreg cells into newborn
Foxp3K276X mice. Mice treated with 0.125 3 106 nTreg cells did not survive to weaning and are not shown.
(B) Representative flow cytometry analysis of lymph node cells gated on CD4+ T cells. Thy1.1 marks the transferred nTreg cell population.
(C) Frequency of nTreg cells (CD4+ gate) in the lymph nodes of treated mice.
(D and E) Bar graphs depicting the average sum (per mouse) of nTreg cells (D), unfractionated lymphocytes and CD4+ T cells (E) recovered from the spleen and
axillary, brachial, superficial inguinal, andmesenteric lymph nodes of treated mice and healthy 6- to 8-week-old control mice. Where indicated, dashed horizontal
linesmark themean values for healthy 6- to 8-week-old control mice (n = 16). This control value does not apply tomice treatedwith 0.1253 106 nTreg cells, which
did not survive beyond 22 days.
(F) Representative flow cytometry analysis of host CD4+ Tconv cells stained for CD44 and CD62L.
(G) Frequency of CD44+CD62L host T cells.
(H) Serum concentration of TNF-a, IFN-g, and IL-17A in treated mice. Colored dots represent individual mice and the horizontal bars indicate mean values.
Treatment dose key: 0.1253 106 nTreg cells (green, n = 16); 0.253 106 nTreg cells (orange, n = 9); 0.53 106 nTreg cells (blue, n = 26); 1.03 106 nTreg cells (red,
n = 10); control (black, n = 9); three to five experiments per nTreg cell dose. Ns, not significant; *p < 0.05, **p < 0.005, ***p < 0.0005. Error bars represent SEM.
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106 cells (Figure 3D). Antigen-specific Treg cells may expand in
some diseases that are associated with chronic inflammation;
thus a reduction in Treg cell numbers can be consistent with
a sustained decrease in disease activity (Curotto de Lafaille
et al., 2008; Miyara et al., 2006; Schmitz-Winnenthal et al.,
2009). Mice that received 1.0 3 106 nTreg cells plus 4 3 106
Tconv cells also showed reductions in several of the disease
manifestations associated with Foxp3 deficiency. The total
numbers of lymphocytes (data not shown), CD4+ T cells, and B
cells were reduced to numbers similar to those of normal mice
(Figure 3E). The proportion of naive host T cells increased from
48% to 56% (Figures 3F and 3G).
Inflammatory bowel disease is a prominent feature of Foxp3
deficiency. However, mice treated with nTreg cells alone still
developed transmural lymphocytic infiltration in the colon.
Though extensive, this infiltrate was not associated with a
marked reduction in mucin production or with extensive crypt
elongation (Figure 3H). When the Treg cell compartment of
treated mice contained both nTreg and iTreg cells, the infiltrates
were reduced, as reflected by decreased colitis scores (Fig-
ure 3I). Tissue infiltration of other organs, including the lung
and liver, were also reduced (data not shown) and serum con-
centrations of TNF-a, IFN-g, and IL-17A were lower, consistent
with improvement in the other disease manifestations (Fig-
ure 3J). Thus, a stable population of iTreg cells was produced
in vivo from Tconv cells and this process correlated with marked
reductions in lymphoproliferation, cytokine production, and
pathologic tissue infiltration of many organs, including the colon.
To ascertain that the contribution of CD4+ Tconv cells to the
rescue was Foxp3 dependent, we used rescued Thy1.2+
Foxp3DEGFP mice as the source of naive Thy1.2+ DTconv cells.
Foxp3DEGFP mice express a nonfunctional Foxp3DEGFP fusion
protein and untreated mice develop an autoimmune lymphopro-
liferative disorder that is indistinguishable from that of
Foxp3K276X mice (Lin et al., 2007). We therefore combined 1 3
106 Thy1.1+ nTreg cells from Foxp3EGFP mice with 4 3 106
Thy1.2+ DTconv cells from rescued Foxp3DEGFP mice and used
these cells in our treatment experiments. Linear regression
analysis of the weight gain, in which the DTconv cells lacked a
functional Foxp3 allele, overlapped that seen when nTreg cells
were used alone and was reduced when compared to the
nTreg + Tconv cell transfer experiments (Figure 3A, n = 8). Other
manifestations of disease were worse and included increased
CD4+ T cell activation and proliferation, B cell proliferation, and
elevated serum concentrations of proinflammatory cytokines
(Figures 3B–3J). These measurements indicated a level of
disease activity that was similar to that seen when nTreg
cells were used alone, confirming that it was the capacity of
Tconv cells to express Foxp3 that was associated with their
therapeutic potential.
Next, we determined the effect of reducing the number of
iTreg cells generated in vivo by transferring 1 3 106 nTreg plus
1 3 106 Tconv cells, which decreased the number of Tconv by
75%. The data showed incomplete rescue, with host T cell acti-
vation, tissue infiltration, and colitis scores that fell between
monotherapy with nTreg cells alone and the combination
therapy with 1 3 106 nTreg plus 4 3 106 Tconv cells (Figure S1
available online). Although the total number of Treg cells presentat the end of the experiments was similar in the two treatment
groups, the frequency and number of iTreg cells reflected the
size of the starting Tconv cell population. Similar results were
obtained when we replaced the missing Tconv cells with 3 3
106 EGFP DO11.10 TCR transgenic T cells (Figure S2). At
50 days, 3.6% of CD4+ T cells expressed the DO11.10 TCR,
and none of these were EGFP+. These data demonstrated that
a reduction in iTreg cell numbers reduced their clinical effect,
that the frequency and number of iTreg cells reflected the size
of the starting Tconv cell population, and that iTreg cells are
generated and maintained through antigen specific selective
pressure.
Last, we replaced the Tconv cells with iTreg cells produced
in vitro, as this approach is a feasible source of Treg cells
when considering adoptive transfer immunotherapy in humans.
It seemed plausible that those iTreg cells generated in vivo in
response to the specific needs of the host might be functionally
different from the iTreg cells derived in vitro from a randomly
selected polyclonal population. To compare the two types of
iTreg cells, we treated Foxp3-deficient pups with 1 3 106
in vitro-generated Thy1.1+ iTreg cells and 13 106 Thy1.2+ nTreg
cells. All mice that received a combination of in vitro-generated
iTreg cells and nTreg cells survived and their weight gain ex-
ceeded that seen when nTreg cells were used alone (Figure 3A,
n = 6). Approximately 50% of the surviving iTreg cells remained
EGFP+ and comprised 4% of the total EGFP+ Treg cell popula-
tion, consistent with long-term stability of iTreg cells generated
in vitro (Figure 3B). Markers of disease activity improved relative
to mice that received nTreg cells alone and were similar to the
transfers where mice received nTreg cells plus the higher dose
of Tconv cells (Figures 3C–3J). Thus, in vitro generated iTreg
cells could largely substitute for iTreg cells derived in vivo, indic-
ative of the functional similarity of the two iTreg cell populations.
Depletion of iTreg Cells
Maintaining tolerance requires the continued presence of
nTreg cells, as determined by nTreg cell depletion studies in
adult mice (Kim et al., 2007). To investigate the role of iTreg cells
in maintaining tolerance, we utilized a similar strategy involving
selective iTreg cell depletion from successfully treated mice.
For these experiments, we created C57BL/6 transgenic mice
that expressed the diphtheria toxin receptor (DTR) under the
control of the Foxp3 promoter (Foxp3DTR mice, Figure S3). In
Foxp3DTR mice, a single 50 mg/kg injection of diphtheria toxin
(DT) resulted in elimination of 90% of peripheral blood nTreg
cells by 24 hr. In vitro conversion experiments demonstrated
that 94% of Foxp3+ iTreg cells expressed the DTR. We next
bred Foxp3DTR mice to CD45.1+ Foxp3EGFP mice and used their
progeny as a source of marked CD4+ Tconv cells capable of
expressing both EGFP and the DTR upon appropriate stimula-
tion in vivo.
Following the protocol used for the experiments in Figure 3, we
treated newborn CD45.2+ C57BL/6 Foxp3DEGFP mice with 1 3
106 CD45.2+ EGFP+ nTreg cells from Foxp3EGFP mice mixed
with 4 3 106 CD45.1+ EGFPDTR Tconv cells isolated from
Foxp3EGFP/DTR+ mice. Littermate controls received 1 3 106
CD45.2+ EGFP+ nTreg cells mixed with 43 106 CD45.1+ EGFP
Tconv cells that lacked the DTR transgene. Both groups of mice
gained weight up to 50 days, similar to the previous treatmentImmunity 35, 109–122, July 22, 2011 ª2011 Elsevier Inc. 113
Figure 3. In Vivo-Derived iTreg Cells Contribute to Tolerance
(A) Linear regression analysis of weight change over time after intraperitoneal adoptive transfer of the indicated number of nTreg and Tconv cell populations into
newborn Foxp3K276X mice (red – 1.0 3 106 nTreg cells, n = 10; green – 13 106 nTreg cells + 43 106 Tconv cells, n = 29; orange – 1 3 106 nTreg cells + 43 106
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all mice were injected with 50 mg/kg of DT every other day for
15 days and analyzed 5 days later. Only those mice where the
transferred Tconv cells carried the DTR transgene lost weight
(Figure 4A). Flowcytometry analysis of the spleens and lymphno-
des from control mice revealed that half of the surviving CD45.1+
cells expressed Foxp3 and that 33%of all EGFP+ Treg cells were
iTreg cells derived by conversion from Tconv cells. In mice that
received Tconv cells carrying the DTR transgene, there were no
EGFP+CD45.1+ iTreg cells remaining after the series of injections,
although the population of CD45.1+ EGFP T cells was main-
tained (Figure 4B). Although the frequency and number of nTreg
cells in both groups was similar (Figures 4C and 4D), the
frequency of host CD4+ T cells expressing the FoxpDEGFP allele
(dimEGFPsignal) increased from5%to9% in iTreg cell-depleted
mice (Figure 4B, middle boxed cells). This suggested pressure to
replace the depleted iTreg cells. Lymphoproliferation and an
increase in the frequency of host CD44hi CD62Llo CD4+ T cells
occurred after iTreg cell depletion, and a higher proportion of
host CD4+ T cells expressed IFN-g (Figures 4E–4I). The lungs
from iTreg cell-depleted mice showed increased perivascular
and peribronchiolar inflammatory infiltrates that contained
macrophages, plasma cells, lymphocytes, and mononuclear
cells (Figure 4J). In addition, there were prominent interstitial infil-
trates, with mononuclear cells and macrophages in the alveolar
spaces. The liver, small intestine, and colons also contained
mixed inflammatory infiltrates (Figure 4K). These data demon-
strated a pathologic increase in host T cell activation in the
absence of iTreg cells thatwasmostmarked atmucosal surfaces
and was consistent with a requirement for iTreg cells throughout
the lifespan of the mouse.
Phenotypic and Transcriptional Analysis of Treg Cell
Subsets
We investigated the molecular basis for the contribution of
in vivo-derived iTreg cells to tolerance by comparing their cell
surface phenotype and gene expression profile with those of
nTreg cells from the same mice. Flow cytometric analysis of
iTreg and nTreg cells from Foxp3K276X mice treated with 1 3
106 nTreg cells and 4 3 106 Tconv cells showed that both Treg
cell subsets had similar cell surface levels of CD25, CD62L,
CD44, CD103, GITR, Helios, and CTLA-4 (Figure 5A). Expression
of Programmed death-1 (PD-1), which plays an important role in
iTreg cell formation and function, was increased on iTreg cells
(Francisco et al., 2009). Granzyme B was increased in nTregDTconv cells from Foxp3DEGFP mice, n = 8; blue – 1 3 106 nTreg cells + 1 3 106
group.
(B) Representative FACS analysis of lymph node cells from the indicated group
ulations: nTreg cells in first and third panels, Tconv cells in the second panel, or
(C) Frequency of nTreg and iTreg cells.
(D and E) Bar graphs depicting the average sum of nTreg cells (D), CD4+ T cells, o
inguinal ,and mesenteric lymph nodes of treated mice. Dashed horizontal lines ma
cells are shown in pink.
(F) Representative FACS analysis of host CD4+ Tconv cells stained for CD44 and
(G) Frequency of CD44+CD62L host T cells.
(H) Representative sections from the colons of the indicated mice stained with h
(I) Colitis scores from treated mice. Colored dots represent individual mice and t
(J) Serum concentration of TNF-a, IFN-g, and IL-17A in treated mice. Data from
facilitating direct comparison; *p < 0.05, **p < 0.005, ***p < 0.0005. Error bars recells, and iTreg cells had a minor population that did not express
Helios. Thus, we could only identify a few subtle differences in
phenotype based on expression of several cell surface and
intracellular proteins.
Next, we compared the gene expression profile of pooled
EGFP+ Thy1.1+ iTreg cells with that of EGFP+ Thy1.1 nTreg cells
sorted from the spleens and lymph nodes of treated mice (Fig-
ure 5B). In aggregate, there were 3491 probe sets that were
differentially expressed relative to naive Tconv cells. Of these,
2651 probe sets (76%) were common to both iTreg and nTreg
cells, with 1290 that were overexpressed and 1361 that were
underexpressed (Figure 5C, Table S1). Overexpressed genes
that are prototypical of the nTreg cell transcriptosome included
Itgae, Izkf2, Ctla4, Il2ra, Nrp1, Il10, Dusp4, Icos, Socs2, Ahr,
and Ikzf4. Underexpressed genes included Cd4, Itk, Ikzf1,
Sox4, Il4ra, Il6ra, and Il7r. This set of common probe sets con-
tained approximately half (302/603) of the microarray probes
that defined the Treg cell genetic signature in another study
(Hill et al., 2007). A direct comparison of probe sets within the
intersection identified only 4 genes with significant differences
in expression between the two types of Treg cells (Eif2s3y,
Ddx3y, Kdm5d, and C1qb). Further analysis showed that nearly
all probe sets identified as ‘‘unique’’ were directionally concor-
dant, being overexpressed or repressed in both iTreg and nTreg
cells relative to naive Tconv cells, albeit at different levels
(Table S2 and Table S3). Another 10% (62/603) of the canonical
Treg cell probe sets were found among these groups. Thus, the
gene expression profiles of iTreg and nTreg cells isolated from
treated mice were similar to each other and to the published
nTreg cell genetic signatures.
The gene expression profile of iTreg cells produced in vitro
and analyzed 3 days after induction is distinct from that of nTreg
cells isolated from healthy animals (Haribhai et al., 2009). Other
data demonstrates that there are important transcriptional
differences between iTreg cell subsets based on the method of
Foxp3 induction and the stability of the corresponding iTreg cell
phenotype (Feuerer et al., 2010). However, when we compared
the genetic signatures of iTreg cells established in vivowith newly
generated iTreg cells produced in vitro, we found striking differ-
ences in the gene expression profiles. A total of 5915 probe
sets were differentially regulated when compared to Tconv cells.
The intersection between these two iTreg cell subsets contained
only 1150 probe sets (Table S4, Table S5, and Table S6, Fig-
ure 5D). A number of prototypical Treg cell genes were not iden-
tified as commonly regulated, including Ikzf2, Klrg1, Il1rl1,iTreg cells generated in vitro, n = 6; three to seven experiments per treatment
s. Analysis is gated on CD4+ T cells. Thy1.1 marks different transferred pop-
in vitro-produced iTreg cells in the fourth panel.
r CD19+ B cells (E) recovered from the spleen and axillary, brachial, superficial
rk the mean values for healthy 6- to 8-week-old control mice (n = 16), and iTreg
CD62L.
ematoxylin and eosin.
he horizontal bars indicate mean values.
1 3 106 nTreg cell treatment group shown in Figure 2 are repeated here for
present SEM.
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Figure 4. Selective iTreg Cell Depletion from Treated C57BL/6 Foxp3DEGFP Mice
(A) Weight change over time following intraperitoneal adoptive transfer of 1 3 106 Foxp3EGFP nTreg cells + 4 3 106 Foxp3EGFP Tconv cells (nTreg+Tconv, blue,
n = 3) or 13 106 Foxp3EGFP nTreg cells + 43 106 Foxp3EGFP/DTR+ Tconv cells (nTreg+TconvDTR, red, n=6) into newborn Foxp3-deficient mice. Diphtheria toxin
was injected every other day for 15 days beginning at 50 days of age (arrow) and analyzed 5 days later. Two experiments were performed.
(B) FACS analysis of lymph node cells gated on CD4+ T cells. CD45.1 marks the transferred Foxp3EGFP and Foxp3EGFP/DTR+ Tconv cell populations.
(C) Frequency of nTreg and iTreg cells after DT treatment.
(D and E) Average numbers (±SEM) of Treg cells (D), total lymphocytes and CD4+ T cells (E) isolated from the peripheral lymphoid tissues of the indicated mice
post DT treatment.
(F and G) FACS analysis of CD44 and CD62L expression (F) and frequency of CD44+CD62L cells (G) in the host (Foxp3DEGFP) CD4+ Tconv population.
(H and I) Representative FACS analysis (H) and cell frequencies (I) of host CD4+ Tconv cells stained for IFNg after DT treatment.
(J and K) Representative sections from the lung (J), colon, liver, and small intestine (K) of the indicated mice stained with hematoxylin and eosin.
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Figure 5. Comparison of iTreg and nTreg Cells from Treated Mice
(A) Representative cell surface marker analysis of CD4+EGFP+ lymph node iTreg (red) or nTreg (blue) cells stained as indicated.
(B) Hierarchical clustering of probe sets significantly regulated in iTreg cells derived in vivo (top), nTreg cells from the samemice (middle), and in vitro-derived iTreg
cells 72 hr after Foxp3 induction (bottom), versus naive Tconv cells from healthymice. The scale represents fold change relative to Tconv cells (3 fold to +3 fold).
(C) Venn diagram depicting the number of commonly and uniquely regulated probe sets in the in vivo derived iTreg and nTreg cell transcriptional signatures. Bar
graphs compare the fold change in expression of select prototypical genes found within the canonical Treg cell transcriptosome.
(D) Venn diagram depicting the number of commonly and uniquely regulated probe sets in the in vivo-derived iTreg and in vitro derived iTreg cell genetic
signatures. Bar graphs compare the fold change in expression of the same genes shown in Figure 5C.
(E) Methylation status of the CpG motifs in the Treg cell-specific demethylation region (TSDR) of conserved noncoding sequence 2 (CNS2) in Foxp3. Residue
numbers represent individual CpG motifs in reference to the transcription initiation site of Foxp3.
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Figure 6. TCR Repertoire Analysis of iTreg and nTreg Cells from Treated Mice
(A) Representative iTreg and nTreg cell spectratype analysis with Vb2 or Vb8.3 50 PCR primers.
(B) Bar graphs comparing the utilization of Jb segments by Vb2 and Vb8.3-containing iTreg and nTreg cell clones.
(C) Venn diagrams showing the distribution of unique and overlapping iTreg and nTreg cell CDR3 amino acid sequences of Vb2 and Vb8.3-containing clones
isolated from individual mice. The number of sequences in each category and the Morsita-Horn Similarity Index (MHI) for the comparison are shown. Ln-rank
versus ln-rank frequency plots for each repertoire are shown below the corresponding Venn diagram.
Immunity
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The iTreg cell intersection included 37% of the nTreg cell tran-
scriptosome identified by Hill et al. (2007). Thus, iTreg cells
produced and maintained in vivo are far more similar to nTreg
cells from the same mice than to iTreg cells generated in vitro.
Although in vitro-derived iTreg cells are clearly functional, they
may require additional signals to acquire genetic and pheno-
typic stability. Interestingly, CpG islands in the Foxp3 promoter
of in vivo-derived iTreg cells were extensively methylated,
suggesting that Foxp3 expression in iTreg cells is either less
stable than that of nTreg cells or is maintained by factors other
than this type of epigenetic mechanism (Figure 5E).
TCR Repertoire Comparisons of Treg Cell Subsets
The similar transcriptional profiles of nTreg and iTreg cells
implied common mechanisms of suppression. Other factors,
such as differences in antigenic specificity, might therefore118 Immunity 35, 109–122, July 22, 2011 ª2011 Elsevier Inc.underlie the requirement for iTreg cells and the selective pres-
sure to retain iTreg cells in treated mice. To investigate this
possibility, we isolated iTreg cells derived from Tconv cells and
nTreg cells from spleens and lymph nodes (brachial, axillary,
mesenteric, and superficial inguinal) of three treated Foxp3K276X
BALB/c mice and compared their TCR repertoires by TCR-b
spectratype analysis and CDR3 sequencing. Each treated
mouse received a different aliquot of cells pooled from two to
three mice as in previous experiments. Fragment analysis using
22 Vb-Cb primer pairs showed a predominantly Gaussian length
distribution for most Vb in the nTreg cell populations withmodest
skewing away from this pattern in iTreg cells (Figure S4). These
data indicated that a broad distribution of b-chains was found
in both nTreg and iTreg cell TCRs.
To compare the TCR repertoires of iTreg and nTreg cells, we
selected Vb2 and Vb8.3 for further analysis based on the similar
distribution of CDR3 lengths seen in all three mice (Figures 6A,
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PCR, cloned, and sequenced, and the sequences were com-
pared at both the nucleotide and amino acid levels. We obtained
acombined total of 3289 in-frame reads from1509 iTregand1780
nTreg clones, and these encoded 1964 unique CDR3 polypep-
tides. (Table S7, Figure S5). Nucleotide sequence analysis re-
vealed that the pattern and frequency of Jb utilization was asso-
ciated with the Vb segment and not with the type of Treg cell
(Figure 6B). CDR3 amino acid sequence analysis for each Vb
revealed that there was limited overlap between the predicted
iTreg and nTreg cell CDR3 polypeptides (Figure 6C, 3%–15%
overlap). In agreement with this observation, the Morista-Horn
similarity index (MHI) was <0.1 in three of the six iTreg versus
nTreg cell TCR CDR3 comparisons, indicating very little similarity
between the two populations (Figure 6C). Ln-rank versus ln-rank
frequency plots revealed an excellent fit for a power law-like com-
ponent in 10/12 of the repertoires analyzed (R2 > 0.95). Because
of this power law-like relationship, the distributions are similar at
all scales of measurement. Several repertoires also contained
a second component consisting of a few high rank clonotypes,
as seen in the analysis of recall responses (Naumov et al., 2006).
Consistent with the Tconv cell origin of iTreg cells, MHI values
from pooled Vb sequence comparisons (Figure S6) were similar
to those from other studies that compared the TCR-a repertoires
of nTreg cells with that of Tconv cells in mice expressing a trans-
genic TCR-b chain (Hsieh et al., 2006; Pacholczyk et al., 2006;
Wong et al., 2007). Most nonoverlapping sequences were found
in a single individual, confirming that Treg cell TCR repertoires
are largely private (‘‘private’’ TCRs, average 97.5%). For the
handful of overlapping sequences, the situation was reversed
and many CDR3 sequences were recovered from two or more
individuals (‘‘public’’ TCRs, average 58%). Most of the frequently
recovered (R4 times) clones were found among the overlapping
sequences and many of these were generated by more than one
DNA rearrangement (convergent sequences) involving the addi-
tion of ‘‘N region’’ nucleotides not found in the germline.
Among Vb8.3 sequences, two CDR3 regions were seen three
to four times more frequently than the next most common CDR3
regions. Clone 1 from mouse 3 had a CDR3 length of 15 amino
acids (CASSDLGHLNTEVFF) and was recovered 29 times from
the iTreg cell library and 26 times from the nTreg cell library, indi-
cating this favored TCR-b chain was selected into both nTreg
and Tconv cell lineages. This unusual occurrence generated
a marked increase in the MHI relative to the percent overlap.
Removing this one sequence from the analysis resulted in an
MHI of 0.148, a value in line with the other comparisons. In
contrast to this overlapping sequence, clone 56 from mouse 2
had a CDR3 length of 14 amino acids (CASRETGGYAEQFF)
and was recovered 42 times from the nTreg cell library only. In
aggregate, these data demonstrated that the iTreg and nTreg
cell TCR repertoires were largely ‘‘private’’ and nonoverlapping.
‘‘Public’’ b-chains occurred rarely, although when present they
were 20 times more likely to be found in TCRs that contributed
to both iTreg and nTreg cell responses.
DISCUSSION
Foxp3-deficient mice have an otherwise intact immune system,
and they lack systemic inflammation in the early neonatal period.These features of Foxp3 deficiency, together with the aggressive
nature of the autoimmune disease that subsequently develops
in untreated mice, made this an ideal model for our studies
designed to examine the role of in vivo-derived iTreg cells in
tolerance induction. The studies herein identify iTreg cells as
an essential, nonredundant regulatory subset that acts synergis-
tically with nTreg cells to enforce peripheral tolerance.
Although nTreg cells were provided by adoptive transfer
immunotherapy shortly after birth, we found that the frequency
of in vivo derived iTreg cells was substantial, as it was in the
lymphopenia-colitis model (Haribhai et al., 2009). We also found
that iTreg cells generated in vitro through a TGF-b-dependent
pathway largely substituted for those iTreg cells derived
in vivo, suggesting that the two sources of iTreg cells were func-
tionally equivalent. We did not directly examine the TGF-b
dependence of the in vivo production of iTreg cells in this
model, so a significant contribution from the TGF-b-independent
CD25+CD69hiCD62LintFoxp3 Treg cell precursor population
cannot be excluded (Schallenberg et al., 2010). Indeed, the
recovery of half as many iTreg cells after 50 days, when the iTreg
cells were derived in vitro rather than in vivo, might argue that
more than one iTreg cell production pathway is operational.
Regardless of the mechanisms supporting iTreg cell induction,
these data reinforce the conclusion that the iTreg cell induction
pathways are important tolerogenic mechanisms, both in the
setting of chronic inflammation and in normal individuals.
Our initial investigations into the mechanisms underpinning
the functional synergy between iTreg and nTreg cells focused
on comparing the gene expression profiles of the two cell types,
which were found to be remarkably similar. One explanation
for this similarity is that each transcriptional signature is a com-
posite of several Treg cell subsets, which could tend to blur
distinctions between the two Treg cell types (Feuerer et al.,
2010). Nevertheless, the current data argue strongly that iTreg
and nTreg cells share overlapping effector mechanisms. Gene
expression profiles do not exclude a skewed reliance on certain
Treg cell mediators like IL-10, which showed 2.2-fold increase
in the in vivo-derived iTreg cells over nTreg cells isolated from
the same mice. Other potential distinctions between the two
Treg cell subsets include increased expression of PD-1 by iTreg
cells and Gzm B by nTreg cells, and differences in localization.
We also found that the transcriptional signature of iTreg cells
produced in vivo was more similar to nTreg cells than to iTreg
cells produced in vitro. The most likely explanation for the differ-
ences in gene expression between iTreg cells produced in vivo
and in vitro is that the profile of iTreg cells generated in vitro is
largely a function of TCR, TGF-b, and IL-2-mediated signaling,
at least shortly after induction (Hill et al., 2007). Indeed, the
gene expression profile of iTreg cells produced in vitro 72 hr
after induction is independent of Foxp3 (Haribhai et al., 2009).
We have not yet examined the transcriptome of iTreg cells pro-
duced in vitro and subsequently allowed to achieve equilibrium
in treated mice. On the basis of the current results, this gene
expression profile is anticipated to closely match that of both
iTreg cells derived in vivo and nTreg cells.
If iTreg and nTreg cells share similar effector mechanisms, as
suggested by their overlapping gene expression signatures,
then other factors must contribute to the capacity of iTreg
cells to complement the function of nTreg cells. For example,Immunity 35, 109–122, July 22, 2011 ª2011 Elsevier Inc. 119
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different TCR specificities than those found in nTreg cells, as
we observed. These results shed light on the origins of in vivo-
derived iTreg cells. Published data demonstrate that some nTreg
cells can lose Foxp3 expression and survive as ‘‘ex-Treg’’ cells
(Yang et al., 2008; Zhou et al., 2009). In our experiments, such
cells would be sorted with the Tconv cells and might re-express
Foxp3 after transfer (Lathrop et al., 2008). A substantial overlap
between nTreg and iTreg cells could therefore indicate that the
two populations were clonally related, implying that iTreg cells
were ‘‘ex-Treg’’ cells that reacquired Foxp3 expression and
suppressive capability under the conditions of our experiment.
Similarly, iTreg cells could be a special population of Tconv cells
poised to express Foxp3 on the basis of their shared TCR
specificity with nTreg cells (Schallenberg et al., 2010). Again,
substantial TCR repertoire overlap would be predicted, if
this shared specificity was created at the clonal level during
the cellular expansion that occurs following b-selection in the
thymus. From another perspective, iTreg cells might come
from those Tconv cells that bear no clonal relationship to nTreg
cells, given the well-documented differences in the TCR ligand
affinity requirements for the selection of nTreg and Tconv cells
in the thymus (Jordan et al., 2001). Here, the predicted result
would be essentially no TCR-b CDR3 overlap between the two
populations, which is largely what we observed, particularly
when considering that peripheral Treg cells probably contain
a mixture of nTreg and iTreg cells. A recent estimate places
the frequency of iTreg cells in the peripheral Treg compartment
at 4%–7% (Lathrop et al., 2008). We estimate that the iTreg
cell frequency in rescued Foxp3 mutant mice is closer to
10%–15%. Such misidentified iTreg cell TCRs would create an
apparent overlap in the iTreg versus nTreg cell TCR comparisons
and may well be a contributor to the small overlap observed in
our studies. Thus, our work is most consistent with naturally
arising nTreg and iTreg cell populations with distinct TCR
repertoires, indicating the two populations are clonally unrelated.
Because there are theoretically 1015 different TCRs that can be
generated, the <1 3 106 different TCR-b chains found within an
individual mouse virtually assures that these randomly selected
repertoires are largely unique to each individual (i.e., ‘‘private’’)
(Quigley et al., 2010). Thus, we expected that there would be little
overlap in TCR-b CDR3 sequences from mouse to mouse, as we
observed. However, a much higher frequency of the overlapping
sequences in our experiments are ‘‘public,’’ which could indicate
that these were the most abundant clones in the donor mice,
that iTreg and nTreg cells share clonal identity, and that the reper-
toires are largely overlapping. Several lines of evidence argue
against this point of view. First, many private nTreg and iTreg
cell sequences were equally abundant, based on the frequency
of their recovery. Thus abundant clones are not restricted to
the overlapping component of the repertoires. Second, if one
source of overlap derives from misidentified iTreg cells within
the transferred nTreg pool, these clones may be numerically
advantaged at the time of transfer, relative to new iTreg cells
that arise in transfer recipients. Furthermore, misidentified iTreg
clones that are present in the nTreg cell inoculatemay be particu-
larly important, since they arise in healthy mice. It follows that
thesecloneswouldbe found frequently in theoverlappingcompo-
nent of the Treg repertoires, and that they would also be more120 Immunity 35, 109–122, July 22, 2011 ª2011 Elsevier Inc.likely to be public if they fill a ubiquitous antigen-specific niche
left vacant by nTreg cells. Indeed, public sequences are seen in
well-characterized antigen-specific CD4+ and CD8+ Tconv cell
responses (Kedzierska et al., 2004; Menezes et al., 2007).
A different explanation for the overlapping ‘‘public’’ CDR3
sequences deserves special attention because it has little to
do with antigen specificity. It has been proposed that an essen-
tial characteristic of ‘‘public’’ CDR3 sequences is that they are
generated by ‘‘convergent recombination’’ (Venturi et al., 2008).
In this proposal, the number of different ways that a particular
TCR CDR3 amino acid sequence can be generated by germline
recombination is an important determinant of TCR production
frequency and therefore of TCR sharing, quite apart from the
antigen specificity of the TCR (Quigley et al., 2010). In other
words, certain TCR-b amino acid sequences are more likely to
be ‘‘public’’ because they are more frequently generated in the
thymus. In our studies, public TCR-b sequences generated by
convergent recombination would also be more likely to be over-
lapping, given that each new TCR-b sequence is paired with
a different TCR-a chain, generating a new TCR and an indepen-
dent opportunity for clones to be selected into either the iTreg
or nTreg cell pool. Indeed, we found that the most frequently
identified public, overlapping TCR-b chain amino acid sequence
was generated by seven unique nucleotide sequences. Some of
our data therefore support this latter model.
It is important to note that in our experiments, the size and
complexity of both Treg cell TCR repertoires is fixed because
there can be no new production of Foxp3+ cells by the host.
This experimental design may have expanded the opportunity
to observe the generation of iTreg cells in vivo as well as the
expansion of a few high rank clonotypes. Most of our TCR reper-
toires fit a two-component model, with a power law-like compo-
nent and a component consisting of a few high rank clonotypes.
This indicates that peripheral selection events occur after
adoptive transfer. Given the repertoire differences described
herein, coupled with the profound differences in the thymic
selection requirements of nTreg and Tconv cells, it seems very
unlikely that iTreg and nTreg cells will recognize identical sets
of self-antigens and foreign antigens and that they will do so at
comparable frequencies. Nevertheless, we make no a priori
claim about the antigen specificity of the responses analyzed,
and the reader should draw a distinction between diversity
(unique TCR sequences) and specificity (antigens recognized).
In rescued mice that received both nTreg cells and either
Thy1.1+TconvorThy1.1+ invitro-generated iTregcells,a substan-
tial number of Thy1.1+ Foxp3 cells were maintained long term.
There are a few possibilities for the origin of these cells. A bidirec-
tional linearmodelwhere Tconv cells gain and lose Foxp3 expres-
sion based on the needs of the host has been proposed and is
consistent with the data (Haribhai et al., 2009). In a variation of
this view, some Treg cells are not terminally differentiated and
can adopt alternative TH cell fates (Zhou et al., 2009), or co-
express other TH lineage specification factors that alter their dis-
tribution and homeostatic properties (Koch et al., 2009). It will be
important to determine the cytokines produced by these
Thy1.1+ Foxp3 cells, to compare their TCR repertoire with that
of iTreg and nTreg cells, and to use genetic tools tomap cell fates
in future experiments. Rational design of adoptive transfer immu-
notherapy with iTreg cells hinges upon this type of information.
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Mice
Foxp3EGFP, Foxp3DEGFP, and Foxp3K276X mice on BALB/c and C57BL/6 back-
grounds were generated and screened as described (Haribhai et al., 2007; Lin
et al., 2007; Lin et al., 2005). DO11.10 mice were obtained from the Jackson
Laboratory and bred on to the Rag1–/– Foxp3EGFP background. Rescued
Foxp3K276X/ K276X females and Foxp3 K276X males were mated for generating
litters in which all progeny were Foxp3 deficient. Mice expressing the simian
DTR cDNA under the control of foxp3 transcriptional control elements
(Foxp3DTR) were generated as described in the Supplemental Experimental
Procedures. The Animal Resource Committees at the Medical College of
Wisconsin and at the University of California, Los Angeles approved all animal
experiments.
Cell Purification and Adoptive Transfer
Pooled splenocytes and lymph node cells were stained with either anti-CD4-
APC, or anti-CD4-Pacific Blue as appropriate, and sorted on the basis of anti-
body and EGFP fluorescence. All sorting was done on a FACSAria (Becton-
Dickenson). The average purity and viability of the sorted CD4+ populations
was 98.0% ± 0.2% and 89.5% ± 0.7% respectively (n = 49). For the Foxp3-
deficient mice rescue experiments, 200 ml of a cell suspension in PBS was
injected into the peritoneal cavity of pups within the first 30 hr after birth.
Diphtheria Toxin Depletion
Rescued Foxp3DEGFP mice (day 50) were given 50 mg/kg of diphtheria toxin
(Sigma Aldrich) in 200 ml of PBS by intra-peritoneal injection daily or every other
day for 15 days. Mice were weighed daily, before each injection when appro-
priate. After the last injection, mice were rested for 5 days and then examined.
For intracellular cytokine analysis, splenocytes were restimulated in culture
with PMA and ionomycin in the presence of Brefeldin A in accordance with
the manufacturer’s instructions (BD Bioscience) for 4 hr, fixed, and permeabi-
lized with 0.1% Triton-X, then stained with antibodies as indicated.
Additional Methods
Detailed descriptions of the methods for the generation of Foxp3DTR mice,
TGF-b1-mediated invitroconversion, colitis scores, flowcytometryandcytokine
analysis, statistics, histology, gene expression analysis, methylation studies,
and CDR3 repertoire analysis can be found in the Supplemental Information.
ACCESSION NUMBERS
The microarray data are available in the Gene Expression Omnibus (GEO)
database (http://www.ncbi.nlm.nih.gov/gds) under the accession number
GSE19512.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, seven tables, and Supple-
mental Experimental Procedures and can be found with this article online at
doi:10.1016/j.immuni.2011.03.029.
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